{
    "organizations": [],
    "uuid": "4d3d6a9ccf8aaaf2f5cc84abd6a1e5a1b298ad50",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-declines-to-approve-aradigms-d/brief-fda-declines-to-approve-aradigms-drug-linhaliq-idUSASB0C2OY",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Declines To Approve Aradigm's Drug Linhaliq",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - Aradigm Corp:\n* ARADIGM RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR LINHALIQ NDA\n* ARADIGM CORP - CRL STATES THAT FDA HAS DETERMINED THAT IT CANNOT APPROVE LINHALIQ NDA IN ITS PRESENT FORM\n* ARADIGM - FDA‘S AREAS OF CONCERN ON LINHALIQ NDA INCLUDE CLINICAL DATA, HUMAN FACTORS VALIDATION STUDY AND PRODUCT QUALITY\n* ARADIGM - CRL ALSO INCLUDED REQUEST TO CONDUCT ANOTHER HUMAN FACTORS STUDY TO SHOW THAT LINHALIQ PRODUCT PACKAGING & INSTRUCTIONS FOR USE ARE EFFECTIVE\n* ARADIGM - CRL REQUESTED ADDITIONAL PRODUCT QUALITY INFORMATION WITH RESPECT TO MICROBIOLOGY & A NEW IN VITRO DRUG RELEASE METHOD DEVELOPMENT REPORT\n* ARADIGM CORP SAYS “WILL REQUEST A MEETING WITH FDA TO DISCUSS TOPICS COVERED IN THE CRL” Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-29T20:12:00.000+02:00",
    "crawled": "2018-01-30T19:01:54.023+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "aradigm",
        "corp",
        "aradigm",
        "receives",
        "complete",
        "response",
        "letter",
        "fda",
        "linhaliq",
        "nda",
        "aradigm",
        "corp",
        "crl",
        "state",
        "fda",
        "determined",
        "approve",
        "linhaliq",
        "nda",
        "present",
        "form",
        "aradigm",
        "fda",
        "area",
        "concern",
        "linhaliq",
        "nda",
        "include",
        "clinical",
        "data",
        "human",
        "factor",
        "validation",
        "study",
        "product",
        "quality",
        "aradigm",
        "crl",
        "also",
        "included",
        "request",
        "conduct",
        "another",
        "human",
        "factor",
        "study",
        "show",
        "linhaliq",
        "product",
        "packaging",
        "instruction",
        "use",
        "effective",
        "aradigm",
        "crl",
        "requested",
        "additional",
        "product",
        "quality",
        "information",
        "respect",
        "microbiology",
        "new",
        "vitro",
        "drug",
        "release",
        "method",
        "development",
        "report",
        "aradigm",
        "corp",
        "say",
        "request",
        "meeting",
        "fda",
        "discus",
        "topic",
        "covered",
        "crl",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}